somatorelin
Peptideexperimental
Growth hormone–releasing hormone (GHRH), also known as somatocrinin among other names in its endogenous form and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH). It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus. — Wikipedia
Clinical trial activity
12 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 1996 (NCT00000380)
Timeline
Indications
Mechanism of action
GHRHR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGrowth hormone–releasing hormone ↗
- ChEMBLCHEMBL2108862 ↗
Also known as
- ghrh
- ghrh
- ghrh ferring
- growth hormone releasing hormone
- growth hormone releasing hormone
- somatorelin
- somatorelin
- somatorelin
- somatorelin
- somatorelin
- somatorelin acetate
- somatorelin acetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03031535 | Phase 1 | Jan 1, 2017 | Celerion, Dauntless Pharmaceuticals |
| NCT02736591 | Phase 3 | Jun 1, 2016 | Cairo University |
| NCT02553603 | Phase 1 | Aug 1, 2015 | The University of Texas, Dallas, University of Texas, Galveston |
| NCT02271282 | Phase 1 | Dec 1, 2014 | Mayo Clinic |
| NCT01410799 | Phase 2 | May 1, 2011 | National Institute on Aging (NIA), University of Pennsylvania |
| NCT00850564 | N/A | Feb 1, 2009 | Harvard University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT00795210 | N/A | Feb 1, 2009 | Harvard University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT00675506 | Phase 2 | Jul 1, 2008 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT00807365 | Phase 2 | Dec 17, 2007 | Harvard University, Johns Hopkins University |
| NCT00720902 | N/A | Feb 1, 2007 | Columbia University |
| NCT00791843 | Phase 2 | Mar 1, 2004 | University of Pennsylvania |
| NCT00000380 | N/A | Jun 1, 1996 | National Institute of Mental Health (NIMH), University of Washington |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 4 | 3 | 2 | 2007 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 2 | 0 | 1 | 2009 |
| University of Pennsylvania | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Celerion | For profit | 1 | 0 | 1 | 2017 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Dauntless Pharmaceuticals | For profit | 1 | 1 | 1 | 2017 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2008 |
| National Institute of Mental Health (NIMH) | Government | 1 | 0 | 1 | 1996 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2011 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Texas, Galveston | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 1996 |
15 organizations
Page 1 / 1